Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 19/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 8/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17843467 | 1.00 | TP53 (0.49) | TP53TLR8TLR7 | |
| SCHEMBL30831287 | 0.95 | TLR8 (0.45) | TP53TLR8TLR7 | |
| SCHEMBL29638794 | 0.91 | TLR8 (0.49) | TP53TLR8TLR7 | |
| SCHEMBL29638792 | 0.90 | TLR8 (0.43) | TP53TLR8TLR7 | |
| SCHEMBL30007216 | 0.88 | TLR8 (0.38) | TP53TLR8TLR7 | |
| SCHEMBL29638797 | 0.86 | TLR8 (0.47) | TLR8TLR7 | |
| SCHEMBL29638774 | 0.85 | TLR8 (0.43) | TLR8TLR7 | |
| SCHEMBL30541811 | 0.84 | TLR8 (0.35) | TP53TLR8TLR7 | |
| SCHEMBL30831270 | 0.81 | TP53 (0.42) | TP53TLR8TLR7 | |
| SCHEMBL29638788 | 0.78 | TLR8 (0.43) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263392-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-08-21 | — | — | US | disclosed |
| CN-117801107-A | Benzazepine derivatives, conjugates containing same and application thereof | 上海迪诺医药科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| WO-2022242724-A1 | NITROGEN-CONTAINING COMPOUND, CONJUGATE CONTAINING SAID COMPOUND, AND APPLICATION THEREOF | 上海迪诺医药科技有限公司 | 2022-11-24 | — | — | WO | disclosed |
| US-20220315537-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | BOLT BIOTHERAPEUTICS, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| CN-114585390-A | Aminobenzazepine compounds, immunoconjugates and uses thereof | 博尔特生物治疗药物有限公司 | 2022-06-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263392-A1 | AMINOBENZAZEPINE COMPOUNDS, IMMUNOCONJUGATES, AND USES THEREOF | IDO2, IDO1, BCR | TP53 1123/4885TLR8 3275/4885TLR7 1547/4885 |
| US-20220315537-A1 | MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS | CCNB1, CCNB2, MUS81 | TP53 1576/4885TLR8 3652/4885TLR7 4387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.